1. Home
  2. BIIB
  3. BIIB News

Latest Biogen Inc. (BIIB) News on August 8, 2025

Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials
BIIB

TipRanks

a month ago

Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
BIIB

Insider Monkey

a month ago

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results

BIIB

MT Newswires

a month ago

Biogen Reports Mobility Gains with New Nusinersen Dose for Spinal Disorder

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
BIIB

GlobeNewswire

a month ago

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

BIIB

MT Newswires

a month ago

Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says

5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call
BIIB

StockStory

a month ago

5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call

Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations
BIIB

Insider Monkey

a month ago

Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations

Can Biogen Save Even More Kids With This New Drug?
BIIB

Investor's Business Daily

a month ago

Can Biogen Save Even More Kids With This New Drug?

Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics
BIIB

GlobeNewswire

a month ago

Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics

BIIB

MT Newswires

a month ago

Biogen to Advance Investigational Spinal Muscular Atrophy Therapy to Registrational Studies

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
BIIB

Business Wire

a month ago

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
BIIB

Investor's Business Daily

a month ago

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB

GlobeNewswire

a month ago

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

BIIB

MT Newswires

a month ago

RBC Raises Price Target on Biogen to $213 From $205, Keeps Outperform Rating

Biogen scores Cannes Festival win with dark humored campaign
BIIB

Pharma Voice

a month ago

Biogen scores Cannes Festival win with dark humored campaign

Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.
BIIB

Insider Monkey

2 months ago

Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
BIIB

Insider Monkey

2 months ago

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Biogen starts dosing in Phase III trial of Friedreich ataxia therapy
BIIB

Clinical Trials Arena

2 months ago

Biogen starts dosing in Phase III trial of Friedreich ataxia therapy

21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity
BIIB

Business Wire

2 months ago

21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity

H.C. Wainwright sees potential competition for Sage from Biogen
BIIB

TipRanks

2 months ago

H.C. Wainwright sees potential competition for Sage from Biogen

BIIB

MT Newswires

2 months ago

Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Treatment

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB

GlobeNewswire

2 months ago

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
BIIB

Zacks

2 months ago

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer
BIIB

GlobeNewswire

2 months ago

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics
BIIB

Investor's Business Daily

2 months ago

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics

Supernus makes depression drug play with $795m Sage buyout
BIIB

Pharmaceutical Technology

2 months ago

Supernus makes depression drug play with $795m Sage buyout

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
BIIB

Investor's Business Daily

2 months ago

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million

Sage, following Setbacks, to sell to Supernus for $561M
BIIB

BioPharma Dive

2 months ago

Sage, following Setbacks, to sell to Supernus for $561M

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025
BIIB

Insider Monkey

2 months ago

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025

1 Profitable Stock with Exciting Potential and 2 to Avoid
BIIB

StockStory

2 months ago

1 Profitable Stock with Exciting Potential and 2 to Avoid

BIIB

MT Newswires

2 months ago

Biogen, UCB Say Dapirolizumab Pegol Phase 3 Study Shows Improvement in Fatigue, Reduction in Disease Activity

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
BIIB

GlobeNewswire

2 months ago

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?
BIIB

Zacks

2 months ago

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
BIIB

GlobeNewswire

2 months ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
BIIB

StockStory

2 months ago

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Biogen and City Therapeutics to develop RNAi therapy
BIIB

Pharmaceutical Technology

2 months ago

Biogen and City Therapeutics to develop RNAi therapy

Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal
BIIB

Insider Monkey

2 months ago

Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal

Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal
BIIB

Simply Wall St.

2 months ago

Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal

BIIB

MT Newswires

2 months ago

Biogen Collaborates With City Therapeutics on RNAi Drug Development

Biogen strikes RNAi deal with City; Aurion withdraws IPO
BIIB

BioPharma Dive

2 months ago

Biogen strikes RNAi deal with City; Aurion withdraws IPO

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB

GlobeNewswire

2 months ago

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

BIIB

MT Newswires

3 months ago

HSBC Adjusts Price Target on Biogen to $121 From $118, Maintains Hold Rating

BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance
BIIB

StockStory

3 months ago

BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance

Why Biogen Inc. (BIIB) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom
BIIB

Insider Monkey

3 months ago

Why Biogen Inc. (BIIB) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

3 Cash-Producing Stocks Skating on Thin Ice
BIIB

StockStory

3 months ago

3 Cash-Producing Stocks Skating on Thin Ice

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
BIIB

StockStory

3 months ago

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

BIIB

Thomson Reuters StreetEvents

3 months ago

Q1 2025 Royalty Pharma PLC Earnings Call

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
BIIB

StockStory

3 months ago

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offering
BIIB

Simply Wall St.

3 months ago

Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offering

BIIB

MT Newswires

3 months ago

Mizuho Cuts Price Target on Biogen to $169 From $207

2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
BIIB

StockStory

3 months ago

2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore

BIIB

MT Newswires

3 months ago

HC Wainwright Adjusts Price Target on Biogen to $187 From $241, Maintains Buy Rating

Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
BIIB

Simply Wall St.

3 months ago

Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

BIIB

Argus Research

3 months ago

Analyst Report: Biogen Inc

BIIB

Argus Research

3 months ago

Market Update: AMZN, BIIB, KLAC, NOV, OKE, TROW, ABNB

BIIB

MT Newswires

3 months ago

Biogen Emerging as 'Leaner, Less Risky' Company, RBC Says

BIIB

MT Newswires

3 months ago

TD Cowen Adjusts Price Target on Biogen to $175 From $200

BIIB

MT Newswires

3 months ago

Goldman Sachs Adjusts Price Target on Biogen to $196 From $197

BIIB

MT Newswires

3 months ago

Morgan Stanley Adjusts Price Target on Biogen to $146 From $152

BIIB

MT Newswires

3 months ago

Canaccord Genuity Adjusts Price Target on Biogen to $220 From $265

BIIB

MT Newswires

3 months ago

Oppenheimer Adjusts Price Target on Biogen to $205 From $255

BIIB

MT Newswires

3 months ago

RBC Cuts Price Target on Biogen to $205 From $217, Keeps Outperform Rating

Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst MS Franchise ...
BIIB

GuruFocus.com

3 months ago

Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst MS Franchise ...

BIIB

Thomson Reuters StreetEvents

3 months ago

Q1 2025 Biogen Inc Earnings Call

BIIB

Pharmaceutical Technology

3 months ago

Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off

Biogen (NasdaqGS:BIIB) Reports Q1 Revenue Growth Despite Decline in Net Income
BIIB

Simply Wall St.

3 months ago

Biogen (NasdaqGS:BIIB) Reports Q1 Revenue Growth Despite Decline in Net Income

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
BIIB

Zacks

3 months ago

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut

Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BIIB

Zacks

3 months ago

Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?
BIIB

Investor's Business Daily

3 months ago

Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?

Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets
BIIB

StockStory

3 months ago

Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets

BIIB

MT Newswires

3 months ago

Biogen's Q1 Non-GAAP Earnings Fall, Revenue Rises; Trims 2025 Non-GAAP Earnings Guidance

Biogen Inc. (BIIB) Q1 Earnings Lag Estimates
BIIB

Zacks

3 months ago

Biogen Inc. (BIIB) Q1 Earnings Lag Estimates

Biogen's results beat estimates on strength in rare disease drugs
BIIB

Reuters

3 months ago

Biogen's results beat estimates on strength in rare disease drugs

Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 90% of the company
BIIB

Simply Wall St.

3 months ago

Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 90% of the company

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
BIIB

Zacks

3 months ago

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics
BIIB

Zacks

3 months ago

Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics

BIIB

Thomson Reuters StreetEvents

3 months ago

Q1 2025 SAGE Therapeutics Inc Earnings Call

Biogen Earnings: What To Look For From BIIB
BIIB

StockStory

3 months ago

Biogen Earnings: What To Look For From BIIB

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
BIIB

Zacks

3 months ago

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron
BIIB

Zacks

3 months ago

The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron

BIIB

MT Newswires

3 months ago

Piper Sandler Adjusts Price Target on Biogen to $115 From $135, Maintains Neutral Rating

BIIB

MT Newswires

3 months ago

Truist Securities Adjusts Price Target on Biogen to $199 From $210, Maintains Buy Rating

BIIB

MT Newswires

3 months ago

HSBC Downgrades Biogen to Hold From Buy, Adjusts Price Target to $118 From $342

BIIB

MT Newswires

3 months ago

RBC Cuts Price Target on Biogen to $217 From $225, Keeps Outperform Rating

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
BIIB

Zacks

3 months ago

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
BIIB

StockStory

3 months ago

1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore

Can Biogen Keep the Beat Streak Alive This Earnings Season?
BIIB

Zacks

3 months ago

Can Biogen Keep the Beat Streak Alive This Earnings Season?

Biogen’s Friedreich’s ataxia treatment authorised in UK
BIIB

Pharmaceutical Technology

3 months ago

Biogen’s Friedreich’s ataxia treatment authorised in UK

BIIB

MT Newswires

4 months ago

Goldman Sachs Adjusts Price Target on Biogen to $197 From $219, Maintains Buy Rating

BIIB

MT Newswires

4 months ago

RBC Lifts Price Target on Biogen to $225 From $221, Keeps Outperform Rating

BIIB

MT Newswires

4 months ago

BMO Capital Adjusts Biogen Price Target to $128 From $139

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
BIIB

Zacks

4 months ago

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi

EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
BIIB

Pharmaceutical Technology

4 months ago

EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s

BIIB

Associated Press Finance

4 months ago

European regulators OK Alzheimer's treatment Leqembi after initial doubts

BIIB

MT Newswires

4 months ago

Wedbush Cuts Biogen Price Target to $121 From $135, Maintains Neutral Rating

BIIB

MT Newswires

4 months ago

Update: Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
BIIB

GlobeNewswire

4 months ago

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

BIIB

MT Newswires

4 months ago

Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU

BIIB

MT Newswires

4 months ago

Goldman Sachs Adjusts Biogen's Price Target to $219 From $245, Keeps Buy Rating

BIIB

MT Newswires

4 months ago

Goldman Sachs Cuts Price Target on Biogen to $219 From $245

Share on Social Networks: